Manufacturing
Bavarian Nordic is one of the few companies in the world able to
supply the growing demand for smallpox vaccines. Our expanding
global manufacturing capacity allows us to confidently plan and
fulfil contracts for our MVA-BN®-based vaccines now and in the
future.
We have significantly strengthened our manufacturing capabilities
and will, at full capacity, be able to produce up to 40 million
doses of IMVAMUNE® per year at our Kvistgård site alone,
which can be expanded if necessary.
Our Berlin
facility has fully implemented the MVA-BN® production
technology and has been granted manufacturing authorisation. This
allows us to produce within our own manufacturing network
significant quantities of clinical materials for our global
development programmes.
These achievements have added flexibility to our global production
network and ensured the supply of current and future vaccines.
